NPC(SH:600713)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 14,081,790,518.45, representing a year-on-year increase of 20.35%[3] - The net profit attributable to shareholders for the same period was CNY 149,157,852.44, reflecting a growth of 12.53% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 149,497,880.77, which is an increase of 24.64% year-on-year[4] - The basic and diluted earnings per share for Q1 2023 were both CNY 0.114, representing a 1.79% increase year-on-year[4] - Net profit for Q1 2023 reached CNY 183.61 million, an increase of 20.93% compared to CNY 151.91 million in Q1 2022[33] - Operating profit for Q1 2023 was CNY 252.13 million, up from CNY 212.66 million in the same period last year, reflecting a growth of 18.59%[33] - The company reported a total comprehensive income of CNY 201.09 million for Q1 2023, compared to CNY 121.04 million in Q1 2022, marking a growth of 66.23%[34] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -3,456,016,751.84, indicating a significant decrease due to increased accounts receivable[4] - As of March 31, 2023, total assets amounted to CNY 32,857,679,992.74, compared to CNY 31,650,959,639.82 at the end of 2022[30] - The company's cash and cash equivalents were CNY 1,387,527,241.52, down from CNY 2,327,195,848.59 at the end of 2022[29] - The company's current liabilities increased to CNY 23,160,572,200.30 as of March 31, 2023, from CNY 22,283,780,193.56 at the end of 2022[30] - The company's inventory increased to CNY 6,186,953,579.93 as of March 31, 2023, compared to CNY 5,787,307,265.45 at the end of 2022, indicating a growth of 6.9%[29] Financing Activities - The company issued a total of CNY 20 billion in short-term financing bonds in 2023, with the first four issuances each totaling CNY 5 billion[9][10] - The company issued a total of RMB 500 million in ultra-short-term financing bonds in both the fifth and sixth phases in 2023[11][12] - The company received a registration notice for medium-term notes with a total amount of RMB 5 billion, valid for two years from February 1, 2023[13] - The company approved a borrowing limit of up to RMB 4 billion from its controlling shareholder for daily operational funding[21] - The company’s subsidiary, Nanjing Medicine Hubei Co., Ltd., was approved to borrow up to RMB 200 million from its minority shareholder[22] - The company reported a significant increase in short-term borrowings, which rose to ¥3,907,325,697.51 in Q1 2023 from ¥1,381,529,730.87 in Q1 2022[39] Research and Development - Research and development expenses increased to CNY 8.37 million in Q1 2023, up 69.00% from CNY 4.95 million in Q1 2022[33] - The company is collaborating with Nanjing New Industry Investment Group to develop a patient service cloud platform with an estimated R&D cost of CNY 2 million, of which the company will bear CNY 1.2 million[24] - The company is also working on a smart scene support system based on supply chain collaboration, with an estimated R&D cost of CNY 10 million, where the company will cover CNY 6 million[24] - Research and development expenses increased to ¥2,741,509.43 in Q1 2023, up from ¥1,683,541.89 in Q1 2022, reflecting a focus on innovation[41] Shareholder Activities - The company had a total of 65,730 common shareholders at the end of the reporting period[7] - The company repurchased and canceled 84,000 restricted stocks at a price of RMB 2.11 per share due to the departure of four incentive targets[17] - The company completed the sale of 8,456,000 shares from its first employee stock ownership plan[19] - The company reported a cash dividend of CNY 1.40 per 10 shares, totaling CNY 183,444,101.68 for the 2022 fiscal year[25] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[44]